Small pieces of glass have been found in Atorvastatin, a generic version of the cholesterol drug Lipitor. The manufacturer, Ranbaxy Laboratories Ltd., cannot explain why the tablets contain glass and has halted production of the medication.
The Federal Drug Administration (FDA) said that production will not resume until the matter has been "thoroughly investigated" and corrected. Ranbaxy maintains that the investigation will be complete in two weeks. The company claims that it's unlikely the tablets pose a risk to patients' health, but concedes that the possibility can't be ruled out.
The FDA says that consumers who are concerned they have a recalled Atorvastatin product should contact the pharmacy where they received the potentially dangerous drug, stop taking the medication if it was recalled, and work with their doctor or pharmacist to receive an alternative product.
Ranbaxy voluntarily recalled 41 lots of Atorvastatin on Nov. 9 due to glass contamination. A smaller recall was issued earlier this summer after a pharmacist discovered a 20-milligram tablet of the drug within a sealed bottle of 10-milligram tablets.
Lipitor and its generic versions are the fifth most popular medications in the country. The FDA is currently working with manufacturers to ensure there's an adequate supply for consumers.
If you believe you were affected by a dangerous drug, like recalled Atorvastatin, we can help. Contact us for a no obligation, free legal consultation. Call 1-866-943-3427, or fill out the form at the top right of this webpage to get started. We can answer your questions and help you determine your legal rights. Our phones answer 24/7, and time is critical. Contact us now.